News
LEXX
3.630
-2.16%
-0.080
Weekly Report: what happened at LEXX last week (0318-0322)?
Weekly Report · 3d ago
Lexaria Bioscience Showcases Drug Delivery Breakthrough
TipRanks · 03/21 17:07
Weekly Report: what happened at LEXX last week (0311-0315)?
Weekly Report · 03/18 11:57
Lexaria Bioscience Welcomes New CFO
TipRanks · 03/14 16:37
Lexaria appoints Nelson Cabatuan as CFO
Lexaria Bioscience Corp. (LEXX) appoints Nelson Cabatuan as CFO. LEXX is -9.3% to $3.99. Cabatuan most recently served as SVP Finance and Operations at Rain Oncology.
Seeking Alpha · 03/14 14:58
Lexaria Appoints Nelson Cabatuan As Chief Financial Officer, Effective Immediately
Lexaria Bioscience Corp. Announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer. Mr. Cabatuan has over 15 years of experience in the life sciences industry. He will lead the Company's financial operations. Lexaria is a global innovator in drug delivery platforms.
Benzinga · 03/14 13:22
Lexaria Bioscience files to sell 1.61M shares of common stock for holders
Seeking Alpha · 03/12 21:20
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Asana, Inc. Fell 11% to $16.72 on Tuesday. Asana reported soft FY25 revenue guidance. ClearOne, Inc., rose 168.4% in the mid-day session. Regulus Therapeutics Inc. Shares rose 74.3% after posting strong quarterly results.
Benzinga · 03/12 18:07
BUZZ-U.S. STOCKS ON THE MOVE-Rumble, Geron, Gold miners
The tech-heavy Nasdaq drove Wall Street higher on Tuesday. The Dow Jones Industrial Average was up 0.49% at 38,961.06. Southwest Airlines and Delta Airlines were among the biggest losers on the NYSE. Gold miners Geron, Anglo Gold Fields and Newmont Mining were down.
Reuters · 03/12 18:00
12 Health Care Stocks Moving In Tuesday's Intraday Session
Regulus Therapeutics stock increased by 94.9% to $2.69 during Tuesday's regular session. Bright Green (NASDAQ:BGXX) shares increased by 66.42%. SCWorx and Assure Hldgs stock moved upwards by 29.33%. Lexaria Bioscience and NRX Pharmaceuticals were among the losers.
Benzinga · 03/12 17:31
FGEN, LEXX and SGLY among mid-day movers
On the Move FGEN, LEXX and SGLY among mid-day movers. ClearOne, Regulus Therapeutics and Simpple Ltd. Gainers: ClearOne (CLRO) and Regulus (RGLS) Losers: Simpples Ltd.
Seeking Alpha · 03/12 16:21
BUZZ-U.S. STOCKS ON THE MOVE-Li-Cycle Holdings, Priority Technology, 3M
Dow Jones Industrial Average was up 0.55% on Tuesday. Top three S&P 500 percentage gainers were Oracle, NVIDIA and 3M. Southwest Airlines and American Airlines Group were among the top three percentage losers. Consumer prices data came in hotter than expected.
Reuters · 03/12 15:54
Weekly Report: what happened at LEXX last week (0304-0308)?
Weekly Report · 03/11 11:53
Lexaria Bioscience Advances Oral Diabetes Treatment
TipRanks · 03/07 18:37
Lexaria to test DehydraTECH GLP-1 product for weight loss, diabetes
Seeking Alpha · 03/05 17:39
Lexaria Tests New Diabetes and Weight Loss Formulations
TipRanks · 03/05 17:37
Lexaria Bioscience Is Maintained at Buy by Maxim Group
Dow Jones · 03/05 16:49
Lexaria Bioscience Price Target Raised to $12.00/Share From $3.00 by Maxim Group
Dow Jones · 03/05 16:49
Maxim Group Maintains Buy on Lexaria Bioscience, Raises Price Target to $12
Benzinga · 03/05 16:41
Lexaria To Begin Diabetes And Weight Loss Animal Study WEIGHT-A24-1
Lexaria Bioscience Corp. Announces details of an 8-week animal study WEIGHT-A24-1 to assess weight loss and blood glucose level control. Multiple DehydraTECH-GLP-1 and DeHydraTech-CBD formulations to be tested. Chronic dosing over a 12-week treatment period Will assess weight lost and blood sugar control. Efficacy through possible brain absorption delivery enhancement to be assessed.
Benzinga · 03/05 14:10
More
Webull provides a variety of real-time LEXX stock news. You can receive the latest news about Lexaria Bioscience Corp through multiple platforms. This information may help you make smarter investment decisions.
About LEXX
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.